Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Rezolute, Inc. (RZLT)

Rezolute completes upLIFT Phase 3 enrollment; topline data expected mid-December 2026

Neutral Impact 3 of 5 other Written later

Rezolute said the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled, with 16 participants, and topline data are expected in mid-December 2026. The filing contains no new efficacy data, and the company said it will continue its expanded access program.

Key points

  • Study is fully enrolled with approximately 16 participants; topline data expected mid-December 2026
  • Earlier in 2026, 7 of the first 8 participants met the primary endpoint responder criterion
  • The eighth participant died one week after enrollment from cancer progression and is counted as a non-responder
  • Statistical significance requires a response rate of at least 56% (95% CI of 30-80%) for 16 participants

The filing

CompanyRezolute, Inc. (RZLT)
Form8-K, current report
Filed with the SECOct 14, 2026, 5:11 PM ET
Accession number0001104659-26-115874

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.